The news keeps getting better for the new GLP-1 weight-loss drugs fromEli Lilly and Novo Nordisk.

Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...

intensifying the company’s race with Novo Nordisk to develop longer-acting insulins. Lilly’s once-weekly insulin, efsitora alfa, reduced the A1C measure of blood sugar comparably to daily ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 9 trades. If we consider the specifics of ...

All dos­es of No­vo Nordisk’s Ozem­pic are ex­pect­ed to face “in­ter­mit­tent short­ages” in Eu­rope dur­ing the fourth quar­ter of the year, es­pe­cial­ly low­er dos­es, ...

Update: Adds company statement about Ozempic availability in the U.S. Novo Nordisk (NVO) has said in a note published by the European Medicines Agency that the supply shortage of its diabetes drug ...

Late last year, Novo Nordisk responded to a growing shortage of popular Ozempic with a plan to cut down on production of its older diabetes med Victoza to make room for more Ozempic. Still ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are big pharma peers. They're also each other's biggest rivals, especially in the all-important market for weight-loss drugs, in which both are ...

After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. Novo’s semaglutide cut the ...

LON­DON — Af­ter a re­cent spate of set­backs, No­vo Nordisk has raised the cur­tain on da­ta de­tail­ing semaglu­tide’s abil­i­ty to cut the risk of heart fail­ure … ...

Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to ...

Novo Nordisk A/S’s Wegovy reduced deaths and illness from Covid in a large study that took place during the pandemic, more evidence of the blockbuster shot’s benefits beyond weight loss.